We are live on
!
Find out more
Ginkgo Bioworks
DNA
DNA
190 hedge funds and large institutions have $2.68B invested in Ginkgo Bioworks in 2022 Q1 according to their latest regulatory filings, with 70 funds opening new positions, 66 increasing their positions, 31 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
113% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 31
71% more funds holding in top 10
Funds holding in top 10: 7 → 12 (+5)
63% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 43
16% more funds holding
Funds holding: 164 → 190 (+26)
0.44% less ownership
Funds ownership: 1.71% → 1.27% (-0.44%)
30% less call options, than puts
Call options by funds: $23.4M | Put options by funds: $33.5M
64% less capital invested
Capital invested by funds: $7.39B → $2.68B (-$4.71B)
Holders
190
Holders Change
+26
Holders Change %
+15.85%
% of All Funds
3%
Holding in Top 10
12
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+71.43%
% of All Funds
0.19%
New
70
Increased
66
Reduced
31
Closed
43
Calls
$23.4M
Puts
$33.5M
Net Calls
-$10.1M
Net Calls Change
-$22.3M
Top Buyers
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$284M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$104M |
| 3 |
Morgan Stanley
New York
|
+$50.8M |
| 4 |
HF
HRT Financial
New York
|
+$37M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$31.9M |
